Upexi prices $7.4M stock and warrant offering
Rhea-AI Filing Summary
Upexi, Inc. has priced a $7.4 million registered direct offering with a single institutional investor, selling 6,337,000 shares of common stock together with warrants to purchase up to 6,337,000 additional shares at a combined price of $1.17 per share and warrant.
The new warrants have an exercise price of $1.50 per share, are exercisable immediately, and will expire five years after issuance, with a forced conversion trigger at $5.00 per share. Upexi plans to use the net proceeds for working capital, general corporate purposes, and its internally managed Solana (SOL) maximum return strategy.
The company will also amend existing warrants covering 3,289,474 shares issued in December 2025, reducing the exercise price from $4.00 to $2.83 per share and lowering the redemption trigger from $8.50 to $7.00, effective upon closing, which is expected on or about February 9, 2026, subject to customary conditions.
Positive
- None.
Negative
- None.
Insights
Upexi raises $7.4M via discounted stock and warrant deal while repricing prior warrants.
Upexi is raising new capital through a registered direct sale of 6,337,000 shares and matching warrants at a combined $1.17. This structure brings immediate cash in from the share sale, with potential additional cash from warrant exercises at $1.50 if the stock trades higher.
The company is also amending existing warrants on 3,289,474 shares, cutting the exercise price from $4.00 to $2.83 and reducing the redemption trigger from $8.50 to $7.00. That makes these older warrants more attractive to holders, which may encourage earlier exercise.
Management states that net proceeds will support working capital, general corporate needs, and its internally managed Solana (SOL) maximum return strategy. Actual dilution and warrant exercise levels will depend on future share price performance and investor decisions after the expected closing on February 9, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Upexi (UPXI) announce about its new financing?
What are the key terms of Upexi’s new warrants in this offering?
How will Upexi (UPXI) use the net proceeds from the $7.4 million offering?
What changes is Upexi making to its existing December 2025 warrants?
When is the closing of Upexi’s registered direct offering expected?
What is Upexi’s business focus and how does Solana (SOL) fit in?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Filing Exhibits & Attachments
12 documentsPress Releases
Agreements & Contracts
Other Documents
- EX-4.1 COMMON STOCK PURCHASE WARRANT 92.4 KB
- EX-4.2 AMENDMENT TO COMMON STOCK PURCHASE WARRANT 14.0 KB
- EX-5.1 OPINION 13.9 KB
- EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.9 KB
- EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 14.9 KB
- EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE 898 B
- EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 9.4 KB
- EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 2.0 KB